Codiak BioSciences, Inc. – NASDAQ:CDAK
Codiak BioSciences stock price monthly change
Codiak BioSciences stock price quarterly change
Codiak BioSciences stock price yearly change
Codiak BioSciences key metrics
Market Cap | N/A |
Enterprise value | 10.94M |
P/E | -0.12 |
EV/Sales | 0.54 |
EV/EBITDA | -0.28 |
Price/Sales | 0.07 |
Price/Book | 0.03 |
PEG ratio | N/A |
EPS | -1.21 |
Revenue | 33.57M |
EBITDA | -36.33M |
Income | -29.23M |
Revenue Q/Q | -97.57% |
Revenue Y/Y | 98.92% |
Profit margin | -195.01% |
Oper. margin | -264.98% |
Gross margin | 65.35% |
EBIT margin | -264.98% |
EBITDA margin | -108.23% |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeCodiak BioSciences stock price history
Codiak BioSciences stock forecast
Codiak BioSciences financial statements
| Dec 2021 | 7.69M | 2.26M | 29.4% |
|---|---|---|---|
| Mar 2022 | 12.70M | -7.80M | -61.44% |
| Jun 2022 | 13.14M | -6.53M | -49.7% |
| Sep 2022 | 28K | -17.16M | -61285.71% |
| Dec 2021 | 171670000 | 118.16M | 68.83% |
|---|---|---|---|
| Mar 2022 | 150070000 | 101.69M | 67.76% |
| Jun 2022 | 132710000 | 88.31M | 66.55% |
| Sep 2022 | 134396000 | 95.46M | 71.03% |
| Dec 2021 | -21.52M | -332K | 208K |
|---|---|---|---|
| Mar 2022 | -20.85M | -182K | 589K |
| Jun 2022 | -14.59M | -171K | 59K |
| Sep 2022 | -10.11M | -9K | 20.09M |
Codiak BioSciences alternative data
| Aug 2023 | 102 |
|---|---|
| Sep 2023 | 102 |
| Oct 2023 | 102 |
| Nov 2023 | 102 |
| Dec 2023 | 102 |
| Jan 2024 | 102 |
| Feb 2024 | 102 |
| Mar 2024 | 102 |
| Apr 2024 | 102 |
| May 2024 | 102 |
| Jun 2024 | 102 |
| Jul 2024 | 102 |
Codiak BioSciences other data
| Period | Buy | Sel |
|---|---|---|
| Sep 2022 | 21866666 | 0 |
| Jan 2023 | 0 | 11454 |
| Feb 2023 | 0 | 16926 |
| Mar 2023 | 0 | 85138 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Sale | HOWZE YALONDA | Common Stock | 1,628 | $0.2 | $319 | ||
Sale | SATHYANARAYANAN SRIRAM | Common Stock | 11,762 | $0.17 | $1,941 | ||
Sale | BARNA NICOLE | Common Stock | 5,373 | $0.17 | $887 | ||
Sale | BARNA NICOLE | Common Stock | 1,932 | $0.17 | $321 | ||
Sale | KONSTANTINOV KONSTANTIN | Common Stock | 7,432 | $0.2 | $1,486 | ||
Sale | KONSTANTINOV KONSTANTIN | Common Stock | 1,932 | $0.2 | $386 | ||
Sale | BAIN LINDA | Common Stock | 13,412 | $0.17 | $2,267 | ||
Sale | WILLIAMS DOUGLAS E | Common Stock | 41,667 | $0.18 | $7,500 | ||
Sale | HOWZE YALONDA officer: See Rema.. | Common Stock | 1,603 | $0.59 | $951 | ||
Sale | BARNA NICOLE officer: See Remarks | Common Stock | 1,274 | $0.59 | $754 |
| Patent |
|---|
Application Filling date: 2 Jul 2020 Issue date: 11 Aug 2022 |
Application Filling date: 4 Feb 2020 Issue date: 11 Aug 2022 |
Application Filling date: 17 Apr 2020 Issue date: 14 Jul 2022 |
Application Filling date: 20 Mar 2020 Issue date: 2 Jun 2022 |
Application Filling date: 4 Feb 2020 Issue date: 12 May 2022 |
Application Filling date: 22 May 2019 Issue date: 20 Jan 2022 |
Application Filling date: 22 Mar 2019 Issue date: 21 Oct 2021 |
Application Filling date: 21 Aug 2017 Issue date: 23 Sep 2021 |
Application METHODS OF MEASURING EXTRACELLULAR VESICLES AND NANOPARTICLES IN COMPLEX MATRICES BY LIGHT SCATTERING Filling date: 21 Jun 2019 Issue date: 26 Aug 2021 |
Application Filling date: 8 Sep 2020 Issue date: 1 Apr 2021 |
-
When is Codiak BioSciences's next earnings date?
Unfortunately, Codiak BioSciences's (CDAK) next earnings date is currently unknown.
-
Does Codiak BioSciences pay dividends?
No, Codiak BioSciences does not pay dividends.
-
What is Codiak BioSciences's stock symbol?
Codiak BioSciences, Inc. is traded on the NASDAQ under the ticker symbol "CDAK".
-
What is Codiak BioSciences's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Codiak BioSciences?
Shares of Codiak BioSciences can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Codiak BioSciences's key executives?
Codiak BioSciences's management team includes the following people:
- Dr. Douglas Edward Williams Ph.D. Pres, Chief Executive Officer & Director(age: 67, pay: $863,680)
- Ms. Yalonda Howze Executive Vice President, Chief Legal Officer, Chief Compliance Officer & Corporation Sec.(age: 53, pay: $322,880)
-
How many employees does Codiak BioSciences have?
As Jul 2024, Codiak BioSciences employs 102 workers.
-
When Codiak BioSciences went public?
Codiak BioSciences, Inc. is publicly traded company for more then 4 years since IPO on 14 Oct 2020.
-
What is Codiak BioSciences's official website?
The official website for Codiak BioSciences is codiakbio.com.
-
Where are Codiak BioSciences's headquarters?
Codiak BioSciences is headquartered at 35 Cambridge Park Drive, Cambridge, MA.
-
How can i contact Codiak BioSciences?
Codiak BioSciences's mailing address is 35 Cambridge Park Drive, Cambridge, MA and company can be reached via phone at +61 79494100.
Codiak BioSciences company profile:
Codiak BioSciences, Inc.
codiakbio.comNASDAQ
102
Biotechnology
Healthcare
Codiak BioSciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing exosome-based therapeutics for the treatment of oncology, neuro-oncology, neurology, neuromuscular diseases, infectious diseases, and other diseases. Its lead product candidates are exoSTING and exoIL-12 exosome therapeutic candidates for the treatment of various solid tumors. The company is also developing exoASO-STAT6, an antisense oligonucleotide targeting the STAT6 transcription factor; and exoVACC, a modular platform for constructing precision vaccines. It has a collaboration agreement with the Jazz Pharmaceuticals Ireland Limited, Sarepta Therapeutics, Inc., Kayla Therapeutics S.A.S., Washington University, Ragon Institute of MGH, MIT, and Harvard. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Cambridge, MA 02140
CIK: 0001659352
ISIN: US1920101060
CUSIP: 192010106
